BusinessAdmin•Yahoo Finance RSS•7 hours ago
Chardan Reaffirms Buy Rating for Iovance Biotherapeutics
Chardan continues to support Iovance Biotherapeutics with a 'Buy' rating, citing strong potential in its cell therapy innovations.
- • Chardan has maintained a 'Buy' rating on Iovance Biotherapeutics, indicating confidence in the company's future performance.
- • The firm believes that Iovance's innovative cell therapy approach positions it well in the competitive biopharmaceutical market.
- • Analysts at Chardan are optimistic about upcoming clinical trial results that could significantly impact Iovance's stock value.
Source: Yahoo Finance RSS
Read original →
